At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Post-Mkt 10-15 19:20:58 EDT
2.25
-0.04
-1.75%
盘后2.32
+0.07+3.06%
19:16 EDT
High2.31Low2.21Vol201.14K
Open2.26D1 Closing2.29Amplitude4.25%
Mkt Cap34.02MTradable Cap21.61MTotal Shares15.12M
T/O455.85KT/O Rate2.09%Tradable Shares9.60M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CervoMed Updates Investors with New Regulatory Presentation
TIPRANKS  ·  10-15 04:30
CervoMed Updates Investors with New Regulatory Presentation
Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)
TIPRANKS  ·  10-14 00:55
Roth MKM Reaffirms Their Buy Rating on CervoMed (CRVO)
CervoMed reports encouraging biomarker data in Phase 2a trial
TIPRANKS  ·  10-13 20:58
CervoMed reports encouraging biomarker data in Phase 2a trial
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  10-13 19:40
Wall Street Analysts Are Bullish on Top Healthcare Picks
CervoMed presents initial data from neflamapimod trial
TIPRANKS  ·  10-12
CervoMed presents initial data from neflamapimod trial
CervoMed Says Phase 2a nfvPPA Trial of Neflamapimod Reduces Plasma NfL over 12 Weeks
Reuters  ·  10-12
CervoMed Says Phase 2a nfvPPA Trial of Neflamapimod Reduces Plasma NfL over 12 Weeks
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at Isftd 2026
THOMSON REUTERS  ·  10-12
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at Isftd 2026
CervoMed - Neflamapimod Generally Well Tolerated with no New Safety Signals Identified
THOMSON REUTERS  ·  10-12
CervoMed - Neflamapimod Generally Well Tolerated with no New Safety Signals Identified
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
GlobeNewswire  ·  10-12
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
CervoMed Updates Investor Presentation and Disclosure Practices
TIPRANKS  ·  10-10
CervoMed Updates Investor Presentation and Disclosure Practices
CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-05
CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock
Simply Wall St.  ·  10-01
Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock
Canaccord Genuity Sticks to Its Buy Rating for CervoMed (CRVO)
TIPRANKS  ·  09-29
Canaccord Genuity Sticks to Its Buy Rating for CervoMed (CRVO)
CervoMed Advances Neflamapimod Tablet and Dosing Strategy
TIPRANKS  ·  09-29
CervoMed Advances Neflamapimod Tablet and Dosing Strategy
CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated
TIPRANKS  ·  09-28
CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated
CervoMed neflamapimod update removes key overhang, says Jones
TIPRANKS  ·  09-28
CervoMed neflamapimod update removes key overhang, says Jones
CervoMed announces PK results with new neflamapimod oral tablet formula
TIPRANKS  ·  09-28
CervoMed announces PK results with new neflamapimod oral tablet formula
CervoMed Plans Neflamapimod 100 Mg Twice-Daily Regimen for Future Clinical Trials
Reuters  ·  09-28
CervoMed Plans Neflamapimod 100 Mg Twice-Daily Regimen for Future Clinical Trials
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
THOMSON REUTERS  ·  09-28
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
CervoMed - Introduces New 50 Mg Neflamapimod Tablet for Twice-Daily Dosing
THOMSON REUTERS  ·  09-28
CervoMed - Introduces New 50 Mg Neflamapimod Tablet for Twice-Daily Dosing

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--